A Business at a Glance
0 of 1 daily views used (1 remaining). Sign up free for +5 more daily views (6 total), or try AAPL for a full preview.
ELITE PHARMACEUTICALS INC /NV/
ELTP
$415M
Mkt Cap
$0.39
+2.11%
ELITE PHARMACEUTICALS INC /NV/ (ELTP) has a current P/E ratio of 9.7, compared to its historical median P/E of 5.3. The stock is currently considered Expensive based on its historical valuation range.
ELITE PHARMACEUTICALS INC /NV/ (ELTP) has a 5-year average return on invested capital (ROIC) of 26.5%. This indicates strong capital allocation and a potential competitive advantage.
ELITE PHARMACEUTICALS INC /NV/ (ELTP) has a market capitalization of $417M. It is classified as a small-cap stock.
ELITE PHARMACEUTICALS INC /NV/ (ELTP) does not currently pay a regular dividend.
Based on historical P/E analysis, ELITE PHARMACEUTICALS INC /NV/ (ELTP) appears expensive. The current P/E of 9.7 is 85% above its historical median of 5.3. The estimated fair value CAGR (P/E method) is 13.1%.
ELITE PHARMACEUTICALS INC /NV/ (ELTP) operates in the Pharmaceutical Preparations industry, within the Healthcare sector.
ELITE PHARMACEUTICALS INC /NV/ (ELTP) reported annual revenue of $84 million in its most recent fiscal year, based on SEC EDGAR filings.
ITEM 1. BUSINESS Elite Pharmaceuticals, Inc., a Nevada corporation (the “Company”, “Elite”, “Elite Pharmaceuticals”, the “registrant”, “we”, “us” or “our”) was incorporated on October 1, 1997 under the laws of the State of Delaware, and its wholly-owned subsidiary, Elite Laboratories, Inc. (“Elite Labs”), was incorporated on August 23, 1990 under the laws of the State of Delaware. On January 5, 2012, Elite Pharmaceuticals was reincorporated under the laws of the State of Nevada. We are a specialty pharmaceutical company principally engaged in the development and manufacture of oral, controlled-release products, and the manufacture of generic pharmaceuticals. Our strategy includes developing generic versions of controlled-release drug products with high barriers to entry. We occupy manufacturing, warehouse, laboratory and office space at 135, 144 and 165 Ludlow Avenue in Northvale, NJ (the “Northvale Facility”).
| Metric | TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|---|
| Revenue | 140M | 84M | 57M | 34M | 32M | 25M |
| Net Income | 43M | -4.3M | 20M | 3.6M | 8.9M | 5.1M |
| EPS | $0.04 | $-0.00 | $0.02 | $0.00 | $0.01 | $0.00 |
| Free Cash Flow | 17M | 5.8M | -4.0M | -2.4M | 6.0M | 2.9M |
| ROIC | 65.9% | 41.1% | 29.0% | 16.3% | 31.2% | 14.9% |
| Gross Margin | 51.1% | 47.7% | 46.5% | 48.6% | 45.9% | 46.8% |
| Debt/Equity | 0.01 | 0.03 | 0.03 | 0.04 | 0.05 | 0.09 |
| Dividends/Share | $0.00 | - | - | - | - | - |
| Operating Income | 50M | 20M | 11M | 3.7M | 5.1M | 2.1M |
| Operating Margin | 35.7% | 23.3% | 19.1% | 10.8% | 15.7% | 8.3% |
| ROE | 54.0% | -7.8% | 46.5% | 13.1% | 43.0% | 38.0% |
| Shares Outstanding | 1,074M | 1,068M | 1,005M | - | 890M | - |
| Metric | |||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||||
| Revenue | N/A | N/A | 12M | N/A | 7.5M | 7.6M | 18M | 25M | 32M | 34M | 57M | 84M | 140M |
| Gross Margin | N/A | N/A | 64.1% | N/A | 52.9% | 37.9% | 44.3% | 46.8% | 45.9% | 48.6% | 46.5% | 47.7% | 51.1% |
| R&D | 4.0M | 15M | 12M | 8.3M | 9.6M | 7.6M | 5.5M | 5.1M | 4.1M | 6.2M | 6.9M | 8.0M | 6.1M |
| SG&A | 2.1M | 2.9M | 2.9M | 2.1M | 2.3M | 3.1M | 3.3M | 3.3M | 4.5M | 5.1M | 7.1M | 9.0M | 12M |
| EBIT | -5.3M | -17M | -8.3M | -7.4M | -9.1M | -9.2M | -2.3M | 2.1M | 5.1M | 3.7M | 11M | 20M | 50M |
| Op. Margin | N/A | N/A | -66.5% | N/A | -121.4% | -121.0% | -12.7% | 8.3% | 15.7% | 10.8% | 19.1% | 23.3% | 35.7% |
| Net Income | -97M | 29M | -10.0M | 25M | -3.7M | -9.3M | -2.2M | 5.1M | 8.9M | 3.6M | 20M | -4.3M | 43M |
| Net Margin | N/A | N/A | -79.8% | N/A | -49.2% | -122.6% | -12.5% | 20.0% | 27.6% | 10.4% | 35.5% | -5.1% | 31.0% |
| Non-Recurring | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 97K | 0 | 1.3M | 0 | 0 | 0 |
| Returns on Capital | |||||||||||||
| ROIC | -29.8% | -63.7% | -26.3% | -21.4% | -22.0% | -29.7% | -16.3% | 14.9% | 31.2% | 16.3% | 29.0% | 41.1% | 65.9% |
| ROE | 214.9% | -49.9% | 29.4% | 95.6% | -24.3% | N/A | -55.0% | 38.0% | 43.0% | 13.1% | 46.5% | -7.8% | 54.0% |
| ROA | -545.0% | 115.2% | -34.6% | 74.3% | -11.3% | -33.6% | -9.1% | 19.9% | 29.0% | 9.4% | 32.3% | -4.8% | 34.3% |
| Cash Flow | |||||||||||||
| Op. Cash Flow | -4.2M | 15M | -2.8M | -7.9M | -4.8M | -6.8M | -1.8M | 3.2M | 6.5M | 3.3M | -3.2M | 7.5M | 19M |
| Free Cash Flow | -4.3M | 15M | -4.7M | -9.0M | -5.0M | -6.8M | -1.8M | 2.9M | 6.0M | -2.4M | -4.0M | 5.8M | 17M |
| Owner Earnings | -5.1M | 14M | -3.8M | -9.0M | -6.1M | -8.2M | -3.2M | 1.9M | 5.3M | 2.0M | -4.7M | 6.0M | 17M |
| CapEx | 47K | 420K | 1.9M | 1.1M | 181K | 19K | 35K | 330K | 499K | 5.7M | 810K | 1.6M | 1.3M |
| Maint. CapEx | 454K | 582K | 666K | 715K | 996K | 1.3M | 1.3M | 1.3M | 1.2M | 1.3M | 1.3M | 1.2M | 1.1M |
| Growth CapEx | 0 | 0 | 1.3M | 383K | 0 | 0 | 0 | 0 | 0 | 4.5M | 0 | 399K | 172K |
| D&A | 454K | 582K | 666K | 715K | 996K | 1.3M | 1.3M | 1.3M | 1.2M | 1.3M | 1.3M | 1.2M | 1.1M |
| CapEx/OCF | N/A | N/A | N/A | N/A | N/A | N/A | N/A | 10.3% | 7.7% | 171.8% | N/A | 21.8% | 6.9% |
| Capital Allocation | |||||||||||||
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Dividend Yield | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Share Buybacks | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Buyback Yield | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | 0.0% |
| Stock-Based Comp | 478K | 260K | 333K | 358K | 245K | 136K | 62K | 13K | 14K | 39K | 160K | 228K | 202K |
| Debt Repayment | 0 | 1.1M | 210K | 220K | 85K | 407K | 0 | 0 | 857K | 0 | 0 | 0 | 0 |
| Balance Sheet | |||||||||||||
| Net Debt | -6.9M | -5.1M | -9.5M | -9.0M | -5.7M | -850K | 443K | -1.7M | -7.2M | -6.8M | -5.3M | -10M | -21M |
| Cash & Equiv. | 6.9M | 7.5M | 12M | 11M | 7.2M | 2.3M | 1.1M | 3.2M | 8.5M | 7.8M | 7.1M | 12M | 22M |
| Long-Term Debt | 0 | 2.1M | 1.7M | 1.6M | 1.5M | 1.4M | 1.6M | 1.5M | 1.4M | 1.0M | 1.5M | 1.2M | 648K |
| Debt/Equity | 0.00 | -0.07 | -0.06 | 0.06 | 0.33 | -0.57 | 0.15 | 0.09 | 0.05 | 0.04 | 0.03 | 0.03 | 0.01 |
| Interest Coverage | -6.1 | -57.5 | -29.6 | -30.9 | -27.0 | -24.8 | -6.4 | 8.1 | 26.4 | 3.3 | 18.3 | 152.8 | 440.7 |
| Equity | -81M | -35M | -33M | 26M | 4.6M | -2.5M | 11M | 16M | 25M | 29M | 58M | 54M | 80M |
| Total Assets | 24M | 26M | 32M | 34M | 31M | 24M | 25M | 26M | 35M | 41M | 84M | 96M | 126M |
| Total Liabilities | 106M | 61M | 21M | 8.6M | 12M | 13M | 14M | 10M | 9.9M | 12M | 26M | 43M | 46M |
| Intangibles | 6.3M | 6.4M | 6.4M | 6.4M | 7.7M | 6.6M | 6.6M | 6.6M | 6.6M | 6.3M | 6.3M | 5.6M | 5.6M |
| Retained Earnings | -225M | -142M | -143M | -139M | -143M | -152M | -154M | -149M | -140M | -136M | -116M | -121M | -94M |
| Working Capital | 3.8M | 7.3M | 12M | 15M | 8.6M | 2.0M | 1.6M | 6.4M | 12M | 14M | 27M | 46M | 84M |
| Current Assets | 9.9M | 12M | 17M | 18M | 14M | 8.9M | 10M | 12M | 19M | 22M | 40M | 58M | 97M |
| Current Liabilities | 6.2M | 5.1M | 4.6M | 3.3M | 5.1M | 6.9M | 8.6M | 5.8M | 6.7M | 7.8M | 13M | 12M | 13M |
| Per Share Data | |||||||||||||
| EPS | -0.21 | -0.02 | -0.01 | -0.01 | -0.01 | -0.01 | 0.00 | 0.00 | 0.01 | 0.00 | 0.02 | -0.00 | 0.04 |
| Owner EPS | -0.01 | N/A | -0.00 | N/A | -0.02 | -0.01 | N/A | N/A | 0.01 | N/A | -0.00 | 0.01 | 0.02 |
| Book Value | -0.18 | N/A | -0.03 | N/A | 0.01 | -0.00 | N/A | N/A | 0.03 | N/A | 0.06 | 0.05 | 0.07 |
| Cash Flow/Share | -0.01 | N/A | -0.00 | N/A | -0.01 | -0.01 | N/A | N/A | 0.01 | N/A | -0.00 | 0.01 | 0.04 |
| Dividends/Share | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | 0.00 |
| Shares Out. | 459.9M | N/A | 996.9M | N/A | 367.3M | 927.9M | N/A | N/A | 889.8M | N/A | 1.0B | 1.1B | 1.1B |
| Valuation | |||||||||||||
| P/E Ratio | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | 3.0 | N/A | 7.5 | N/A | 9.6 |
| P/FCF | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | 4.4 | N/A | N/A | 80.6 | 24.2 |
| EV/EBIT | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | 3.8 | 4.8 | 12.8 | 22.9 | 7.9 |
| Price/Book | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | 1.1 | 2.6 | 8.8 | 5.2 |
| Price/Sales | N/A | N/A | 21.8 | N/A | 6.1 | 11.3 | N/A | N/A | 1.3 | 1.2 | 1.7 | 4.5 | 3.0 |
| FCF Yield | -2.2% | N/A | -1.5% | N/A | -13.6% | -8.2% | N/A | N/A | 22.5% | -7.5% | -2.7% | 1.2% | 4.1% |
| Market Cap | 193M | N/A | 309M | N/A | 37M | 84M | N/A | N/A | 27M | 32M | 151M | 470M | 417M |
| Avg. Price | 0.17 | 0.31 | 0.27 | 0.21 | 0.12 | 0.09 | 0.08 | 0.07 | 0.05 | 0.04 | 0.10 | 0.35 | 0.39 |
| Year-End Price | 0.42 | 0.24 | 0.31 | 0.14 | 0.10 | 0.09 | 0.07 | 0.06 | 0.03 | 0.03 | 0.15 | 0.44 | 0.39 |
ELITE PHARMACEUTICALS INC /NV/ passes 3 of 9 quality checks, indicating weak fundamentals.
ELITE PHARMACEUTICALS INC /NV/ trades at 9.7x trailing earnings, compared to its 15-year median P/E of 5.3x, suggesting it is currently Expensive relative to its historical range. On a free-cash-flow basis, the stock trades at 24.2x vs a median of 42.5x. The company's 5-year average ROIC is 26.5% with a gross margin of 47.1%. At current prices, the estimated annualized return to fair value is +52.8%.
ELITE PHARMACEUTICALS INC /NV/ (ELTP) has a net profit margin of -5.1%. The company is currently unprofitable.
ELITE PHARMACEUTICALS INC /NV/ (ELTP) generated $6 million in free cash flow in its most recent fiscal year. Positive free cash flow supports dividends, buybacks, and debt reduction.
ELITE PHARMACEUTICALS INC /NV/ (ELTP) has a debt-to-equity ratio of 0.03. This indicates a conservatively financed balance sheet.
ELITE PHARMACEUTICALS INC /NV/ (ELTP) reported earnings per share (EPS) of $-0.00 in its most recent fiscal year.
ELITE PHARMACEUTICALS INC /NV/ (ELTP) has a return on equity (ROE) of -7.8%. A negative ROE may indicate losses or negative equity.
ELITE PHARMACEUTICALS INC /NV/ (ELTP) has a 5-year average gross margin of 47.1%. This indicates decent pricing power.
The Ledger Terminal provides 15 years of financial data for ELITE PHARMACEUTICALS INC /NV/ (ELTP), sourced directly from SEC EDGAR filings. This includes income statements, balance sheets, cash flow statements, and key financial ratios.
ELITE PHARMACEUTICALS INC /NV/ (ELTP) has a book value per share of $0.05, based on its most recent annual SEC filing.
No recent press releases.